Loading
companiesCompany
Incyte
Incyte makes pemigatinib, the first targeted drug approved for bile duct cancer (2020), and the JAK inhibitor ruxolitinib.
Also called: Incyte (incl. MorphoSys US rights)
Overview
Incyte, based in Wilmington, Delaware, and listed as INCY, makes pemigatinib, sold as Pemazyre, the first targeted drug approved for bile duct cancer in 2020, and the JAK inhibitor ruxolitinib, proved in COMFORT-I for myelofibrosis. Pemigatinib was approved for FGFR2-fusion cholangiocarcinoma on the FIGHT-202 trial, but the first-line FIGHT-302 trial against gemcitabine and cisplatin was discontinued; the company also markets tafasitamab with MorphoSys for diffuse large B-cell lymphoma and retifanlimab, and it developed the failed IDO1 inhibitor epacadostat. OnCo links it to biliary tract cancer, lymphoma, anal cancer, Merkel cell carcinoma and myeloproliferative neoplasms. Whether FGFR inhibition can move earlier in bile duct cancer after FIGHT-302 stopped is the open question. Each product has its own page.
Headquarters
Wilmington, DE, US
Scorecard
All companies#29of 1244 companies, score 92
- approved products +24
- phase 3 +9
- phase 1/2 +2
- targets +14
- modalities +6
- regions +6
- 24-month regulatory events +4
- registry trials +30
- failures -3
4 approved, 3 in phase 3, 2 earlier, 7 targets, 547 registry studies. Formula on the scorecards page.
Type
Biotech · INCY
Stage
Public
Website
ApprovedSmall-molecule kinase inhibitor (FGFR1-3)
Pemigatinib · Pemazyre
Pemigatinib was the first targeted therapy for bile duct cancer, for tumours with an FGFR2 gene fusion.
NegativeSmall molecule (IDO1 inhibitor)
An enzyme blocker meant to stop tumours starving T cells of tryptophan. Its 2018 phase 3 failure ended an entire class overnight.
Phase 3small molecule (structure undisclosed or not yet in PubChem)
INCB123667 is an experimental small-molecule drug from Incyte in phase 3 trials for ovarian cancer, with its target not yet stated publicly.
Phase 3small molecule (structure undisclosed or not yet in PubChem)
INCB161734 is an experimental small-molecule drug from Incyte in phase 3 trials for pancreatic ductal adenocarcinoma, aimed at KRAS.
Phase 3bispecific antibody (TGF-beta receptor II x PD-1, per the sponsor's pipeline page; form not stated in the registry record)
INCA33890 is an experimental investigational agent whose form is not stated in the registry from Incyte in phase 3 trials for colorectal cancer, with its target not yet stated publicly.
ApprovedMonoclonal antibody (anti-CD19, Fc-enhanced)
Tafasitamab · Monjuvi
A CD19 antibody given with lenalidomide for lymphoma patients who cannot have a transplant; in 2026 it showed the first frontline gain over R-CHOP in high-risk disease.
Phase 1Monoclonal antibody against mutant calreticulin
INCA033989 is an antibody that recognises only the mutant form of calreticulin found in about a quarter of essential thrombocythaemia and myelofibrosis patients. Unlike existing drugs, which control counts, it targets the diseased clone itself and is in first-in-human trials.
Phase 2Oral PI3K inhibitor
Parsaclisib is an oral pi3k inhibitor from Incyte Corporation, in registered phase 2 trials for diffuse large B-cell lymphoma.
ApprovedAnti-PD-1 monoclonal antibody (IgG4)
Retifanlimab · Zynyz
Retifanlimab is a PD-1 antibody approved for Merkel cell carcinoma and, with chemotherapy, as the first immunotherapy standard for advanced anal cancer.
ApprovedSmall-molecule JAK1/JAK2 inhibitor
Ruxolitinib · Jakafi / Jakavi
Ruxolitinib was the first JAK inhibitor: it shrinks the spleen and relieves symptoms in myelofibrosis and controls blood counts in polycythaemia vera, without eliminating the disease clone.
Notes
top- Incyte holds worldwide rights to tafasitamab (Monjuvi) after the MorphoSys deal. frontMIND (Lancet 2026) showed tafasitamab plus lenalidomide and R-CHOP improved progression-free survival against R-CHOP in high-risk newly diagnosed DLBCL (HR 0.75), the first frontline win over R-CHOP in decades, with a supplemental BLA planned for the first half of 2026.
rctLancet 2026changed practice
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
A new combination for relapsed or refractory follicular lymphoma that adds a CD19-directed antibody to the established lenalidomide and rituximab pairing, with the largest progression-free survival hazard ratio reported in the setting.
rctNew England Journal of Medicine 2012changed practice1,676 citations
COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis
COMFORT-I turned the 2005 discovery of the JAK2 V617F mutation into the first effective medicine for myelofibrosis, transforming symptom control for a disease with no prior standard. Ruxolitinib is still the reference first-line therapy, with fedratinib, pacritinib and momelotinib as alternatives for cytopenic patients. It does not eliminate the malignant clone or reverse fibrosis in most patients.
Similar pages
- TreatmentLenalidomide
Shares frontMIND, Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients, Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (, To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL.
- IdeactDNA-guided switching among FGFR inhibitors
Shares FIGHT-202, FIGHT-302, Pemigatinib, Biliary tract cancer (cholangiocarcinoma).
- Key paperPOD1UM-303/InterAACT-2: retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic anal squamous cell carcinoma
Shares POD1UM-303/InterAACT-2, Retifanlimab, Anal cancer (squamous cell carcinoma).
- TreatmentPipobroman
Shares RESPONSE, Ruxolitinib, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TermMerkel cell polyomavirus (MCPyV) status
Shares POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma), Retifanlimab, Merkel cell carcinoma.
cancers
fronts
drugs
NegativeSmall molecule (IDO1 inhibitor)
Phase 1Monoclonal antibody against mutant calreticulin
Phase 3bispecific antibody (TGF-beta receptor II x PD-1, per the sponsor's pipeline page; form not stated in the registry record)
Phase 3small molecule (structure undisclosed or not yet in PubChem)
Phase 3small molecule (structure undisclosed or not yet in PubChem)
Phase 2Oral PI3K inhibitor
ApprovedSmall-molecule kinase inhibitor (FGFR1-3)
Pemigatinib · Pemazyre
ApprovedAnti-PD-1 monoclonal antibody (IgG4)
Retifanlimab · Zynyz
ApprovedSmall-molecule JAK1/JAK2 inhibitor
Ruxolitinib · Jakafi / Jakavi
ApprovedMonoclonal antibody (anti-CD19, Fc-enhanced)
Tafasitamab · Monjuvi
companies
trials
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in PaA Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionA Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal AdenocarcinomaA Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection aA Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveA Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerAALL1521An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibCOMFORT-IEpacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal CancerExtension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With TafasitamabFIGHT-202FIGHT-302frontMINDINTUITT-NF2Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung CancerPembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)POD1UM-303/InterAACT-2RESPONSERetifanlimab and Ruxolitinib In Solid MalignanciesRollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsSafety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL PatientsStudy of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckStudy to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionStudy to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL